PEPCID RPD Drug Patent Profile
Which patents cover Pepcid Rpd, and when can generic versions of Pepcid Rpd launch?
Pepcid Rpd is a drug marketed by Merck and is included in one NDA.
The generic ingredient in PEPCID RPD is famotidine. There is one drug master file entry for this compound. One hundred and forty-nine suppliers are listed for this compound. Additional details are available on the famotidine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Pepcid Rpd
A generic version of PEPCID RPD was approved as famotidine by FRESENIUS KABI USA on April 16th, 2001.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for PEPCID RPD?
- What are the global sales for PEPCID RPD?
- What is Average Wholesale Price for PEPCID RPD?
Summary for PEPCID RPD
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 83 |
| Clinical Trials: | 35 |
| DailyMed Link: | PEPCID RPD at DailyMed |
Recent Clinical Trials for PEPCID RPD
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Ohio State University Comprehensive Cancer Center | Phase 2/Phase 3 |
| United States Department of Defense | Phase 2 |
| Leidos Life Sciences | Phase 2 |
US Patents and Regulatory Information for PEPCID RPD
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merck | PEPCID RPD | famotidine | TABLET, ORALLY DISINTEGRATING;ORAL | 020752-001 | May 28, 1998 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Merck | PEPCID RPD | famotidine | TABLET, ORALLY DISINTEGRATING;ORAL | 020752-002 | May 28, 1998 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for PEPCID RPD
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Merck | PEPCID RPD | famotidine | TABLET, ORALLY DISINTEGRATING;ORAL | 020752-002 | May 28, 1998 | ⤷ Start Trial | ⤷ Start Trial |
| Merck | PEPCID RPD | famotidine | TABLET, ORALLY DISINTEGRATING;ORAL | 020752-001 | May 28, 1998 | ⤷ Start Trial | ⤷ Start Trial |
| Merck | PEPCID RPD | famotidine | TABLET, ORALLY DISINTEGRATING;ORAL | 020752-002 | May 28, 1998 | ⤷ Start Trial | ⤷ Start Trial |
| Merck | PEPCID RPD | famotidine | TABLET, ORALLY DISINTEGRATING;ORAL | 020752-001 | May 28, 1998 | ⤷ Start Trial | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for PEPCID RPD
See the table below for patents covering PEPCID RPD around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Austria | 374800 | ⤷ Start Trial | |
| Austria | A103080 | ⤷ Start Trial | |
| Australia | 534329 | ⤷ Start Trial | |
| Australia | 5597580 | ⤷ Start Trial | |
| Belgium | 882071 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch